CAS 27314-97-2|Tirapazamine
| Common Name | Tirapazamine | ||
|---|---|---|---|
| CAS Number | 27314-97-2 | Molecular Weight | 178.148 |
| Density | 1.7±0.1 g/cm3 | Boiling Point | 493.6±28.0 °C at 760 mmHg |
| Molecular Formula | C7H6N4O2 | Melting Point | 220ºC |
| MSDS | ChineseUSA | Flash Point | 252.3±24.0 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | tirapazamine |
|---|---|
| Synonym | More Synonyms |
Tirapazamine BiologicalActivity
| Description | Tirapazamine is an anticancer agent that shows selective cytotoxicity for hypoxic cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Cancer |
| References | [1]. Cai TY, et al. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol Cancer Ther. 2014 Mar;13(3):630-42. [2]. Sliwinska J, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2? balance protein levels. Oxid Med Cell Longev. 2012;2012:890826. |
Chemical & Physical Properties
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Boiling Point | 493.6±28.0 °C at 760 mmHg |
| Melting Point | 220ºC |
| Molecular Formula | C7H6N4O2 |
| Molecular Weight | 178.148 |
| Flash Point | 252.3±24.0 °C |
| Exact Mass | 178.049072 |
| PSA | 89.83000 |
| LogP | -0.31 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.777 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 59390 ug/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD - Lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- >36 mg/kg
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Endocrine - other changes Blood - changes in bone marrow (not otherwise specified)
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 89 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 101 mg/kg
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Skin and Appendages - hair Nutritional and Gross Metabolic - weight loss or decreased weight gain
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 19 mg/kg/2W-C
- TOXIC EFFECTS :
- Related to Chronic Data - death
MUTATION DATA - TYPE OF TEST :
- Unscheduled DNA synthesis
- TEST SYSTEM :
- Rodent - rat Mammary gland
- DOSE/DURATION :
- 500 umol/L
- REFERENCE :
- CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 11,1407,1990
- TYPE OF TEST :
- Unscheduled DNA synthesis
- TEST SYSTEM :
- Rodent - rat Mammary gland
- DOSE/DURATION :
- 500 umol/L
- REFERENCE :
- CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 11,1407,1990
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| RTECS | DM0671500 |
Articles36
More Articles| An innovative three-dimensional gelatin foam culture system for improved study of glioblastoma stem cell behavior. J. Biomed. Mater. Res. B. Appl. Biomater. 103(3) , 618-28, (2015) Three-dimensional (3-D) tissue engineered constructs provide a platform for examining how the local extracellular matrix contributes to the malignancy of various cancers, including human glioblastoma ... | |
| Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels. Oxid. Med. Cell. Longev. 2012 , 890826, (2012) Doxorubicin (DOX) causes long-term cardiomyopathy that is dependent on oxidative stress and contractility disorders. Tirapazamine (TP), an experimental adjuvant drug, passes the same red-ox transforma... | |
| Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br. J. Cancer 77 Suppl 4 , 12-4, (1998) Human solid tumours are composed of a significant proportion of hypoxic cells, i.e. cells with oxygen levels lower than those of normal tissues. Tumour hypoxic cells have been shown to have a negative... |
Synonyms
| 4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine |
| 1,2,4-Benzotriazin-3-amine, 1,4-dioxide |
| 3-Amino-1,2,4-benzotriazine 1,4-Dioxide |
| 1,4-Dioxido-1,2,4-benzotriazin-3-ylamine |
| SR 259075 |
| 1,2,4-Benzotriazin-3-amine 1,4-dioxide |
| 4-Hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine SR 259075 SR 4233 Tirazone Win 59075 |
| Tirazone |
| Tirapazamine |
| 3-Aminobenzo[e][1,2,4]triazine 1,4-dioxide |
